For how we live.
A pooled analysis of four trials found depemokimab roughly halved exacerbations, yet it did not significantly improve asthma control or reach the threshold for a meaningful quality-of-life gain.
A registry snapshot of 13,455 adults measures how far the biologic era has moved severe asthma toward remission, and finds the inflammation these drugs target still detectable in most patients.
35% of patients on tezepelumab stopped oral steroids entirely, versus 21% on placebo, without losing asthma control — in a drug that targets inflammation upstream of the eosinophil count doctors usually check.